Events
BioCity, the pioneering life science incubator and business collective opened its doors to one hundred young women from local schools on Tuesday 08 October 2019, to celebrate the tenth annual Ada Lovelace Day.
Reported Additional Positive Phase 2 Data Showing Ridinilazole Improved Quality of Life and Microbiome Preservation Compared to Standard of Care
Lachman Consultant Services, Inc., a leading provider of expert compliance, regulatory affairs, and technical services to life sciences organizations worldwide, will return to the International Society for Pharmaceutical Engineering’s 2019 Annual Meeting.
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will attend several upcoming international conferences.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm and can help reverse some of the damage that’s already been done.
Lotus Clinical Research announced that Neil Singla, MD, Chief Scientific Officer spoke at Arrowhead’s Pain & Migraine Therapeutics Summit in Washington, D.C. on Sept. 23, 2019.
Helsinn announces it will be co-hosting alongside Recordati Rare Diseases, a worldwide leader in rare diseases and orphan drugs, part of Recordati Group, a satellite symposium at the 28th European Academy of Dermatology and Venereology Congress, held this year in Madrid from 9 – 13 October 2019.
Microbix Biosystems Inc. announces it is making two presentations about the performance of its in-vitro diagnostics quality products (IVD Controls) at the 11th European Meeting on Molecular Diagnostics (EMMD) in Noordwijk, The Netherlands, October 9-11, 2019.
MRI evaluation suggests slowing of cartilage damage and potential chondroprotection in osteoarthritis of the knee
Sensyne Health plc, the British clinical AI technology company, announces that its Annual Report and Accounts for the year ended 30 April 2019 is now available on the Group’s website at www.sensynehealth.com/investors.
PRESS RELEASES